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Abstract
Background: Worldwide, chronic obstructive pulmonary disease (COPD) is the fourth cause of
death. Exacerbations have a negative impact on the prognosis of COPD and the frequency and
severity of these episodes are associated with a higher patient mortality. Exacerbations are the first
cause of decompensation, hospital admission and death in COPD. The incidence of exacerbations
has mainly been estimated in populations of patients with moderate-severe COPD requiring
hospital care. However, little is known regarding the epidemiology of exacerbations in patients with
less severe COPD forms. It is therefore possible that a high number of these less severe forms of
exacerbations are underdiagnosed and may, in the long-term, have certain prognostic importance
for the COPD evolution. The aim of this study was to know the incidence and risk factors
associated with exacerbations in patients with COPD in primary care.
Methods and design: A prospective, observational, 3-phase, multicentre study will be performed
involving: baseline evaluation, follow up and final evaluation. A total of 685 smokers or ex-smokers
from 40 to 80 years of age with COPD, without acute respiratory disease or any other long-term
respiratory disease will be randomly selected among the population assigned to 21 primary care
centres. The diagnosis of COPD and its severity will be confirmed by spirometry. Information
regarding the baseline situation, quality of life and exposure to contaminants or other factors
potentially related to exacerbations will be collected. A group of 354 patients with confirmed
COPD of varying severity will be followed for one year through monthly telephone calls and daily
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reporting of symptoms with the aim of detecting all the exacerbations which occur. These patients
will be evaluated again at the end of the study and the incidence of exacerbations and associated
relative risks will be estimated by negative binomial regression.
Discussion: The results will be relevant to provide knowledge about natural history of the initial
phases of the COPD and the impact and incidence of the exacerbations on the patients with mild-
moderate forms of the disease. These data may be important to know the milder forms of
exacerbation wich are often silent or very little expressed clinically.
Background
COPD is characterized by little reversible airflow obstruc-
tion of chronic evolution and progressively incapacity
causing a high morbimortality. Although it is a potentially
avoidable disease, the rise in the prevalence of COPD is
slow and unyielding, with epidemiological projections
foreseeing a growing trend in the next decades and a two-
fold increase in death by this disease in the next 20 years
[1].
In Spain COPD is the fifth cause of death. The IBERPOC
study estimated a prevalence of 9% among the Spanish
population from 40 to 69 years of age and of 23% among
the population of more than 60 years old [2]. This same
study detected that underdiagnosis is high (78.2%) and
that, in addition, it is accompanied by a worrisome under-
treatment (80.7%). It is estimated that COPD makes up
2% of the Spanish healthcare budget representing approx-
imately 0.25% of the gross national product. A recent
study quantified the mean annual cost per patient diag-
nosed with this disease as $ 1,760 [3].
Chronic obstructive pulmonary disease may be diagnosed
based on the clinical history, physical examination and
the data provided by spirometry in primary healthcare. It
has been demonstrated that the quality of the spiro-
metries performed in primary care centres is adequate and
allows effective diagnostic orientation [4]. The proximity
of primary care to the patients also allows the disease to
be approached in the early stages and is where most of the
cases of COPD are attended.
Exacerbations are an important cause of the morbimortal-
ity of these patients, in whom the progressive course of
COPD is often aggravated as a consequence of these epi-
sodes [5]. Exacerbations are the first cause of decompen-
sation, hospital admission and death in COPD which,
particularly in winter, lead to an overload in patients
attended in hospital emergency departments and occupa-
tion of ward beds [6,7]. Moreover, a deterioration in pul-
monary function may be observed, mainly following
bacterial exacerbations [8], as well as in the short and
long-term quality of life [9,10].
In a study performed in Spain in 2,414 outpatients diag-
nosed with chronic bronchitis and follow up of one
month after the exacerbation, recurrence was reported in
up to 21% of the patients. Of these, 32% required hospital
attendance, 16% hospital admission and 51% were
treated in primary care but required adjustment in their
medication [8]. Considering the high prevalence of these
diseases in the population, together with this rate of recur-
rences, which are initially evaluated in primary care, it
may be inferred that this is a health problem with a high
impact of the health status of these patients as well as in
the use of healthcare services. Advances in the knowledge
of the factors which condition the appearance of exacerba-
tions and recurrence would be helpful to adopt preventive
measures and to plan healthcare measures.
Over time different definitions of exacerbations have been
proposed and used which, together with the use of differ-
ent criteria of selection and indexes of patient severity,
have made it difficult to compare the studies published. In
1999 the first consensus was proposed and was later rati-
fied in 2004 [11]. This definition was based on three axes:
the worsening of the conditions of the patients (without
specifying which), acute onset and the need for changes in
the normal treatment of the patient. Later the European
Respiratory Society (ERS) and the American Thorax Soci-
ety (ATS) made a joint consensus definition which con-
siders an exacerbation of COPD to be an event in the
natural development of the disease characterised by a
change in baseline dyspnoea, cough and/or expectoration
of the patients beyond the daily variations in the symp-
toms and which is sufficient to justify a change in treat-
ment [12].
It is difficult to identify exacerbations based on their clin-
ical definitions, thus, a wide variability may be observed
in the different studies in relation to the concept of an
exacerbation [13]. The patients themselves do not associ-
ate the worsening of their disease with the term exacerba-
tion, although they are capable of consistently recognising
the signs and symptoms which define or announce an
exacerbation [14]. Identification of exacerbations is often
based on the episodes referred by the patient, depending
on their degree of memory. In a study by Meek [15], the
concordance between the experience of COPD symptomsBMC Public Health 2009, 9:8 http://www.biomedcentral.com/1471-2458/9/8
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lived and the memory of the same two weeks later was
acceptable, being influenced by the presence and intensity
of the symptoms the day remembered and by the presence
and grade of cognitive deterioration of the patient.
The incidence of exacerbations of COPD in Spain has
recently been estimated in longitudinal studies carried out
in outpatients with moderate-severe COPD, demonstrat-
ing a range of 1.5 – 2 episodes per year [10]. A high per-
centage of these episodes require medical attention and
condition a high prescription of antibiotics. In studies
undertaken in other countries, the incidence of exacerba-
tions in moderate-severe COPD has been estimated to be
2.5 – 3 episodes per patient and year [16]. Nonetheless, it
should be taken into account that a proportion of exacer-
bations do not receive medical care, with there being a cer-
tain degree of underdiagnosis [17] even in hospitalised
patients with respiratory symptoms compatible with
COPD [18]. Undertreatment may represent an accelerated
decline in pulmonary function making early diagnosis
and treatment essential [19].
The frequency of the exacerbations has been related to a
greater degree of severity or deterioration in forced expir-
atory volume in the first second (FEV1) and to the season
of the year [10]. Recurrences of exacerbations treated in
the outpatient clinic have been related to the severity of
COPD and the number of visits to the primary care physi-
cian in the last year. However, the initial severity of the
exacerbation is not related to the recurrence [8]. It has
been described that 50–70% of the exacerbations are due
to infections, although the role of antibiotics in the treat-
ment of an exacerbation and recurrence is controversial
[20]. In a study performed in Spain [21] a relationship
was found between the exacerbations and being a smoker,
low compliance with inhalation therapy and severe
involvement of pulmonary function. Common colds are
associated with a greater severity and duration of exacer-
bations and have also been found to be important predic-
tors of the appearance of an exacerbation. Other factors
reported in the literature which may favour the appear-
ance of exacerbations are environmental pollution, low
temperatures and concomitant heart disease [8,22].
A two-year follow up study of patients with COPD dem-
onstrated a significant worsening in the quality of life of
patients who had exacerbations compared with those who
did not, with this deterioration being greater in patients
with two or more exacerbations. The impact of exacerba-
tions on the quality of life was more important in the
patients with better preserved pulmonary function [23].
There may be an important grade of underdiagnosis of
exacerbations [16], particularly in the cases of mild-mod-
erate COPD. The viral aetiology of most of the exacerba-
tions and the daily variability they present in the clinical
manifestations of COPD may make it difficult for patients
to recognise the beginning of an exacerbation. On review-
ing the literature we did not find any study with a popula-
tional basis designed specifically to respond to the
question regarding the incidence of exacerbations in
patients attended in the community. In most studies the
incidence is estimated from the follow up visits carried
out at intervals of between 6 and 12 months. This may
have repercussions on the quality of memory of the
patients and thus, there may be a certain bias in memory
so that only the most severe exacerbations requiring med-
ical care or hospital admission are reported, while the self-
limited exacerbations or those which reverse with the self-
management of the patient remain unreported in epide-
miological studies.
On the other hand, most studies are performed in popu-
lations attended in hospital services, with the consequent
over-representation of moderate-severe COPD versus the
milder forms of the disease. We therefore considered it
necessary to carry out a multicentre study from primary
care including the exacerbations of the less severe forms of
the disease which are the most prevalent in the casuistry.
The study is therefore designed to better understand the
epidemiology of the exacerbations of the less severe forms
of COPD to know the incidence and the risk factors asso-
ciated with exacerbations in the patients attended in pri-
mary care, including patients with mild involvement who
have seldom been studied in previous investigations on
exacerbations and COPD.
Objectives
Main objectives
1. To know the populational incidence of respiratory exac-
erbations in the COPD patients attended in the commu-
nity.
2. To know the populational incidence of respiratory exac-
erbations in the COPD patients attended in the commu-
nity based on the grade of disease severity.
3. To identify the risk factors associated with the appear-
ance of exacerbations in COPD patients attended in the
community.
Secondary objectives
4. To know the proportion of patients incorrectly diag-
nosed with COPD in primary care offices.
5. To know the influence on the quality of life of COPD
patients in relation to the number of exacerbations pre-
sented.BMC Public Health 2009, 9:8 http://www.biomedcentral.com/1471-2458/9/8
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6. To know the degree of underdiagnosis of exacerbations
in primary care offices.
7. To describe the healthcare resources used by COPD
patients with an exacerbation.
Methods and design
A prospective, observational, populational, multicentre
study will be carried out with a 12-month follow up
divided into three phases (Figure 1): Phase I, initial evalu-
ation with diagnostic confirmation and baseline evalua-
tion of the study subjects; Phase II with a 12-month
follow up to observe the appearance of episodes influenc-
ing an exacerbation and Phase III, the final evaluation.
Study subjects
Patients who are smokers or ex-smokers diagnosed with
COPD from 40 to 80 years of age without acute respira-
tory disease or any other long-term respiratory disease will
be included. This multicentre study will include 21 pri-
mary care centres serving a population of 420,000 inhab-
itants in an urban, semirural and rural area of the zone of
North Barcelona and the Maresme (Barcelona), Spain.
Inclusion criteria
Smokers or ex-smokers from 40 to 80 years of age diag-
nosed with COPD (Codes ICD-10: J43 and J44 or CIAP-2:
R79 and R95) in the database of the computerised clinical
history (e-CAP or OMI-AP) of the healthcare centres par-
ticipating in the study without acute pulmonary disease at
the time of inclusion and who accept to participate and
sign the informed consent.
Exclusion criteria
Patients who have never smoked or patients with: con-
traindications for spirometry, difficulties in communicat-
ing (cognitive deterioration, sensorial disability, language
barriers), severe disease with poor vital prognosis (less
than one year), other active long-term respiratory disease
during the last year (asthma, respiratory tract cancer, pul-
monary thromboembolism, pulmonary tuberculosis,
interstitial diseases, etc.), impossibility to communicate
by telephone to establish the monthly follow up and
patients who do not provide written informed consent to
participate in the study.
Patients presenting acute respiratory disease on recruit-
ment for Phase I will be invited to participate 30 days
afterwards if the exacerbation has subsided. If another
exacerbation is presented after one month the patient will
be definitively excluded from the study. Acute respiratory
disease is understood to be that presented in the 30 days
prior to recruitment and includes: exacerbations of
COPD, respiratory infection or hospital admission due to
respiratory disease.
Phase I patients whose diagnosis of COPD is not con-
firmed on the basis of spirometric studies will be excluded
from phases II and III.
Sample size and selection method
All the calculations were carried out with an alpha risk of
0.05 and the follow up is fixed at one year. We believe that
the incidence of exacerbations may be of around 1 per
year, 2 per year and 4 per year in patients with mild, mod-
erate and severe COPD, respectively. A total of 97 patients
are necessary to estimate a rate of incidence of 1 exacerba-
tion/person-year (with a precision of ± 0.2), 86 patients
are required for a rate of 2 exacerbations/person-year (±
0.3) and 97 patients for a rate of 4 exacerbations/person-
year (± 0.4). To detect a relative risk of 1.7 or more with a
bilateral contrast with a proportion of subjects exposed to
a certain risk factor between 20% and 70%, and guaran-
teeing a power of at least 80%, 116 patients are required if
the rate of incidence of exacerbations between those not
exposed is of 1/person-year, 58 patients if the rate is of 2
and 29 patients for a rate of 4. If the loss to follow up is
estimated to be 15%, 137 mild patients, 102 moderates
and 115 severe patients should be recruited to obtain the
estimations of incidence and relative risk described.
Assuming that 20% of the patients diagnosed with COPD
in the clinical history are mild, 30% moderate, 30% severe
and 20% are not really cases of COPD; to achieve a sample
of 137 mild, 102 moderate and 115 severe patients a total
of 685 patients should be recruited. With this sample can
estimate a proportion of 20% of false diagnosis of COPD
in a electronic medical records, with a precision of ± 0.3%.
With 685 patients participating in Phase I only the first
137 mild patients, the first 102 moderate patients and the
first 115 severe patients identified will be followed. With
this sample a rate of weighted global incidence of between
1 and 4 exacerbations/person-year will be calculated with
a precision of at least ± 0.4. A total of 801 exacerbations is
expected. With this number of exacerbations a proportion
of under-reporting of COPD exacerbations in the compu-
terised clinical history of 20% may be estimated, with a
precision of ± 0.3%.
The objective of the study is centred on the exacerbations
of the less severe forms of COPD which are the most
directly attended in primary care. This is why the severe
and very severe classes of the stratification of severity of
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) [24] were included in the category of severe
patients in the calculation of the sample.
The initial selection of the subjects will be performed ran-
domly from the list of patients who are assigned one of
the ICD-10 codes defining COPD, being stratified by
grade of disease severity (according to data from the clin-
ical history) and by the primary care centre. A letter will beBMC Public Health 2009, 9:8 http://www.biomedcentral.com/1471-2458/9/8
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Flow diagram of the study Figure 1
Flow diagram of the study.
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sent to the subjects selected inviting them to participate in
the study, with an appointment for the visit which will
thereafter be confirmed by telephone.
Study variables
Phase I, initial evaluation
The diagnosis and severity of COPD will be confirmed
according to the GOLD criteria [24] performing a spirom-
etry following a bronchodilation test in a stable setting. A
diagnosis of COPD should be considered in any patients
who has a post-bronchodilator FEV1/FVC ratio < 70%.
The patients will be classified according to the severity of
COPD as: mild (FEV1 ≥ 80%), moderate (FEV1 ≥ 50% and
< 80%), severe (FEV1 ≥ 30% and < 50%) and very severe
(FEV1 < 30%) [24]. The following covariables will be col-
lected in the subjects studied:
1. Baseline evaluation of the study subjects:
1.1 Oxygen saturation by pulsioximetry.
1.2 Usual symptomatology: grade of expectoration, pres-
ence of cough (usually no, occasionally or sometimes,
everyday) and dyspnea with the MRC questionnaire [25].
1.3 Usual medication and treatment related to COPD:
drugs and dosage.
1.4 Controls performed in relation to COPD: periodicity,
healthcare level where carried out (family physician or
pneumology specialist).
1.5 Previous hospital admissions in relation to COPD.
1.6 St. George's Respiratory Questionnaire (SGRQ) qual-
ity of life test [26].
1.7 Six-minute walk test [27].
2. Sociodemographic variables: age, gender, work status,
level of education, municipality of residence, site of home
(rural, semi-urban, urban) and ethnicity.
3. Physical activity usually undertaken, evaluated as
weekly hours invested in: sedentary activities such as read-
ing, watching television, manual activities, walking or
strolling, going upstairs, or any other type of physical
activity or sport.
4. Anthropometric variables: height, weight, waist and hip
circumference.
5. Active and passive smoking exposure.
6. Labour and domestic exposure to possible risk factors
of exacerbations: number of persons residing at home,
presence of children or other chronic patients at home,
presence of pets at home, environmental factors (dust,
smoke, humidity, brusque temperature changes, air-con-
ditioning, paint and solvents, combustible products, pol-
len).
7. Pathological antecedents and use of medications for
other diseases. History of allergies. Vaccination status ver-
sus the influenza virus and pneumococci. The informa-
tion reported by the patient will be compared with
information from the clinical history.
Phase II, 12-month follow up
The variable of interest will be the appearance of an exac-
erbation of COPD. We define an exacerbation as any
event in the natural development of the disease character-
ised by a change in baseline dyspnea, cough and/or expec-
toration of the patient beyond the daily variability and
which is sufficient to justify a change in treatment [12]. A
different episode of exacerbation will be considered when
an interval of clinical stability of at least 72 hours is
observed [28]. To determine the appearance of an exacer-
bation the patients will have a symptom diary at home
and moreover they will be contacted by telephone every
month.
They will be interrogated regarding changes in their usual
symptomatology (expectoration, cough, dyspnea) as well
as in the treatment for their respiratory disease. An
increase in the symptomatology accompanied by a change
in the treatment will be considered as a new event. To
quantify the number of events in the last month indirect
variables (number and type of consultation to healthcare
services, hospital admissions due to COPD, changes in
medication, evolution of the symptoms) will also be col-
lected to know the delimitation of each episode. The
patients will also be asked about the number of days they
have felt worse than usual with respect to their disease, the
number of times they have worsened and improved with
respect to their disease during the last month and the
healthcare resources used during each exacerbation. In
addition, the appearance of respiratory morbidity (pneu-
monia, pulmonary neoplasm, heart failure, pulmonary
embolism and pneumothorax) and death (date and
cause) will be registered.
Each month the clinical histories of the primary care cen-
tres of all the patients followed will be examined, and
when the patient has been hospitalised the clinical histo-
ries of the hospital of admission will be reviewed. With
these data the grade of agreement between the informa-
tion reported by the patient and that registered in the clin-
ical history may be compared.BMC Public Health 2009, 9:8 http://www.biomedcentral.com/1471-2458/9/8
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Phase III, final evaluation
The same variables as in the initial visit will be collected
to detect changes in the quality of life, functional situa-
tion, symptoms, tolerance to effort, use of medication and
use of healthcare resources.
Data collection
Phase I
All the patients of the participating centres with a diagno-
sis of COPD encoded in their clinical history will be listed.
A first screening will be made of these clinical histories
from primary care and the hospital reports related to the
same to exclude the patients with any criteria of exclusion
in their clinical history or whose registered spirometry
parameters are not congruent (FEV1/FVC ratio ≥ 70%)
with a diagnosis of COPD. The patients who have not
been excluded in this first screening will be randomly
selected up to the number of patients required for each
group of severity for each centre. The subjects selected will
be invited to participate by letter and telephone call. If
they do not wish to participate or cannot be located after
10 attempts to contact them on different days and times
they will be substituted by another randomly chosen sub-
ject from the same centre. The patients selected who, at
the time of study inclusion, have an exacerbation of their
respiratory disease will be temporarily excluded and re-
evaluated four weeks later. If the exacerbation situation
persists at this time the patient will be definitively
excluded from the study.
The patients selected will attend their healthcare centre
without having smoked (minimum of 6 hours previously)
or having taken their inhaled medication (12 or 24 hours
previously according to the half life of the active drug). In
the office they will be able to sign the informed consent to
participate in the study. A nurse who is specifically trained
for the study will perform a spirometry with a bronchodi-
lator test. If the result of the spirometry is not compatible
with a diagnosis of COPD, the study will be finished.
If the result of the spirometry is compatible with the diag-
nosis of COPD the tests, measurements and questionnaire
described in the section of study variables will be per-
formed up to completing the groups of 137 mild patients,
102 moderate and 115 severe patients necessary for the
follow up. Since this Phase I cannot be carried out simul-
taneously in all the centres participating in the study to
ensure that the patients remain similarly distributed in
number and severity in the different centres, each centre
will be proportionally assigned the patients of each group
of COPD severity.
The information will be introduced by the nurse in a data-
base during the visit using an electronically supported
case report form (CRF) and portable computer.
Phase II
The first 137 mild patients, 102 moderate and 115 severe
patients detected in
Phase I will participate in the second phase of the study.
One month after the patient in Phase I has been included,
a nurse especially trained for the study will perform the
telephone follow up with the standardised questions
which will allow collection of the variables described in
the section on study variables to detect the appearance of
exacerbations in this period of time. If the patient is
admitted or is unable to respond to the telephone ques-
tionnaire the data will be obtained from the main patient
care provider. If the patient cannot be localised after 10
attempts, the questionnaire will be postponed until the
following month. The telephone follow up will be carried
out monthly in all the patients included in Phase II of the
study. Data collection will also be undertaken with an
electronically supported CRF and a portable computer at
the same time as the telephone follow up.
Each patient included in Phase II will analogously receive
a diary edited specifically for the study to note the changes
in the symptoms of the disease and/or treatment and the
need to use healthcare service due to an exacerbation
daily. This diary is designed graphically thereby helping
the patients to carry out this task. Each page of the diary
collects the information corresponding to one month and
may be taken out so that the patients may hand in the reg-
istry sheet to their primary healthcare centre. If necessary,
the centre may help to solve any doubts regarding this
note taking, although the follow up telephone call may
also be helpful or the patients may call a telephone
number given to all the patients included in the study.
Phase III
The week before completing one year of inclusion in the
study, the patients who have participated in Phase II will
be contacted to be invited to participate in Phase III. The
same tests, measurements and questionnaires performed
at the beginning of the study (Phase I) will be performed
and the patient will be interrogated regarding the appear-
ance of exacerbations during the last month. Assuming
that 15% of the patients will be lost to follow up, it is esti-
mated that 116 mild patients, 86 moderate and 97 severe
patients, according to the initial evaluation of severity,
will participate in this part of the study.
Prior to definitively launching the study, a pilot test will
be undertaken with 50 subjects for the Phase I and the first
month of follow up. Following analysis of this test the
processes which have not worked satisfactorily will be
redesigned.BMC Public Health 2009, 9:8 http://www.biomedcentral.com/1471-2458/9/8
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The period of inclusion of the patients in Phase I is esti-
mated to be of 10 – 12 months, the follow up in Phase II
will be of 12 months and Phase III will be completed in
4–6 months more. Thus, the foreseen duration of the
study is 30 months. At the end of 2009 Phase I results will
be presented and the conclusions and final results of the
study will be available in 2011.
Analysis plan
To respond to objectives 1 and 2 the rate of incidence will
be estimated as the number of exacerbations per patient-
year. To do this, negative binomial regression models will
be used to calculate the incidences and their confidence
intervals [29]. The relative risks (RR) of incidence between
individuals exposed and not exposed to a certain risk fac-
tor will be used to respond to the third objective [29].
With these models the changes observed between the
baseline and final situation will be related as will the
number of exacerbations (objective 5). To determine the
RR of the different variables, bivariate and multivariate
models will be applied adjusting for the potential factors
of confusion. All the analyses will be globally performed,
being weighted for the distribution of severity obtained in
Phase I and according to the severity of the patient.
Descriptive statistics will be carried out of all the variables
collected (objective 7). The number of patients whose
diagnosis of COPD is not confirmed in Phase I, divided by
the total number of patients visited in this phase, will pro-
vide the proportion of patients with an incorrect diagnosis
of COPD in primary care (objective 4). The number of
exacerbations not collected in the clinical histories from
primary care, divided by the number of exacerbations
reported by the patient in Phase II of follow up, will pro-
vide the grade of under reporting of the exacerbations in
primary care (objective 6). All the statistical tests will be
carried out with a bilateral confidence level of 95%.
Ethical considerations
Written informed consent will be requested from all the
patients prior to their inclusion in the study. The patients
will be informed of the objectives of the study as well as
the tests and the follow up to be carried out.
This study has been approved by the Ethical Committee of
Clinical Investigation of the Primary Care Research Insti-
tute Jordi Gol (Barcelona, Spain).
Discussion
The results of the study will provide knowledge regarding
aspects of COPD which are little known, such as the nat-
ural history of the initial phases of the disease and the
impact and incidence of the exacerbations on the patients
with mild-moderate forms of the disease attended at a pri-
mary healthcare level. Most of the current knowledge of
this disease is focused on its most severe forms, in patients
mainly attended in hospital centres, who are possible only
the "tip of the iceberg" of a much deeper problem. We also
expect to provide results related to the incidence and
impact on health of these mild-moderate recurrences,
which, in many cases, are not attended in the healthcare
system until they acquire criteria of severity. This knowl-
edge will allow early intervention strategies for the recur-
rences to be designed, promoting self-care and the early
identification of the symptoms as basic elements to mini-
mise their progression to severity and the use of more
complex healthcare resources. We will detect possible var-
iations in the seasonal incidence of exacerbations in our
setting along with their implications for the planning of
service availability and healthcare resources in the months
of highest incidence. Likewise, we expect to obtain more
in depth knowledge of the risk factors which favour the
exacerbation of COPD, with their implications to provide
schedules to avoid the exposure to these factors.
We believe it will be relevant to provide data related to the
milder forms of exacerbation which are often silent or
very little expressed clinically and which are not usually
seen in the healthcare system. These data may be particu-
larly important in patients with less severe forms of COPD
who, given the chronicity and progressiveness of this dis-
ease, will, in the near future, be among the 5 first cause of
morbimortality in western countries.
One important limitation of this study is the definition of
exacerbation itself and the ability to differentiate the exac-
erbations of COPD from other acute respiratory processes
in patients with the disease. This difficulty will be mini-
mised using the definition adopted by the consensus
between the European Respiratory Society and the Ameri-
can Thoracic Society. This definition also establishes a
minimum period of 72 hours of clinical stability between
one exacerbation and the next. Thus, performing a
monthly follow up will ensure better patient memory
with respect to the exacerbations experienced, thereby
reducing the risk of introducing a memory bias on behalf
of the patients.
At the same time, to carry out a more exhaustive follow up
of the episodes, the clinical histories of the patients will be
reviewed at both an outpatient and hospital level. Moreo-
ver, the patients will be able to personally note down the
changes in their disease and/or treatment in the diary spe-
cifically edited for the study. The results will be compared
with the data from the 3 sources of follow up information
(medical registries, telephone call and symptom diary).
From the experience accumulated in previous studies we
expect the rate of participation in the study to be high, par-
ticularly if we take into account the implication of the pro-
fessionals of the primary healthcare centres of theBMC Public Health 2009, 9:8 http://www.biomedcentral.com/1471-2458/9/8
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patients. On the other hand, since this is an observational
study which does not involve the performance of invasive
tests or pharmacologic interventions, we believe this will
also facilitate recruitment and patient inclusion.
To increase the validity and reliability of the diagnostic
tests performed, the collaborating personnel of the study
will be specially trained to perform these tests and the
same spirometry model will be used in all the patients.
In conclusion, we believe that the results of the study will
provide knowledge to know the characteristics of the
patients with COPD attended in primary care better and
will help to achieve the recommendations of the manage-
ment of the disease contained in the national and interna-
tional guidelines [24,30].
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